Altimmune Inc (ALT) ticks all the boxes for top investors with its surprise performance of -14.43% last month.

Altimmune Inc (NASDAQ: ALT) on Monday, plunged -9.92% from the previous trading day, before settling in for the closing price of $6.65. Within the past 52 weeks, ALT’s price has moved between $5.28 and $14.05.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 104.92%. The company achieved an average annual earnings per share of -9.55%. With a float of $76.22 million, this company’s outstanding shares have now reached $77.01 million.

The extent of productivity of a business whose workforce counts for 59 workers is very important to gauge. In terms of profitability, gross margin is -3857.69%, operating margin of -191365.38%, and the pretax margin is -199076.92%.

Altimmune Inc (ALT) Insider and Institutional Ownership

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Altimmune Inc is 1.03%, while institutional ownership is 53.08%. The most recent insider transaction that took place on Aug 19 ’24, was worth 110,547. In this transaction Director of this company sold 16,011 shares at a rate of $6.90, taking the stock ownership to the 41,958 shares.

Altimmune Inc (ALT) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -9.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.99% during the next five years compared to 3.48% growth over the previous five years of trading.

Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators

Altimmune Inc (ALT) is currently performing well based on its current performance indicators. A quick ratio of 13.10 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23065.55.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.69 in one year’s time.

Technical Analysis of Altimmune Inc (ALT)

The latest stats from [Altimmune Inc, ALT] show that its last 5-days average volume of 2.95 million was superior to 2.25 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 42.56%. Additionally, its Average True Range was 0.45.

During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 3.54%, which indicates a significant decrease from 14.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.00% in the past 14 days, which was lower than the 79.16% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $6.91, while its 200-day Moving Average is $7.08. Now, the first resistance to watch is $6.49. This is followed by the second major resistance level at $6.99. The third major resistance level sits at $7.27. If the price goes on to break the first support level at $5.71, it is likely to go to the next support level at $5.43. The third support level lies at $4.93 if the price breaches the second support level.

Altimmune Inc (NASDAQ: ALT) Key Stats

Market capitalization of the company is 461.31 million based on 71,125K outstanding shares. Right now, sales total 430 K and income totals -88,450 K. The company made 10 K in profit during its latest quarter, and -22,850 K in sales during its previous quarter.